Skip to main content

Advertisement

Table 2 Summary of Predictors of mortality in HIV-associated TB patients in Serowe/Palapye district Botswana 2013

From: Human immunodeficiency virus-associated tuberculosis care in Botswana: evidence from a real-world setting

Variables Hazard ratio (95% CI) P Adjusted HR (95% CI) P
Age group, year
 < 35 1
 35–59 0.89 (0.46–1.7) 0.722 1.5 (0.75–3) 0.245
 ≥ 60 3.15 (1.28–7.73) 0.012 4.8 (1.8–13) 0.002
 Male sex 1.22 (0.67–2.23) 0.513
 Unemployed 1.2 (0.59–2.42) 0.627
Smoker 2.53 (0.76–8.42) 0.130 0.66 (0.13–3.4) 0.619
 Body weight < 50 kg 2.1 (0.94–4.71) 0.072 1.8 (0.7–4.5) 0.205
 Smear positive PTB 0.5 (0.27–0.93) 0.028
 Extrapulmonary 1.12 (0.59–2.13) 0.739
 Previous TB 0.74 (0.27–2.01) 0.571
 Fever 1.58 (0.85–2.94) 0.153
 Productive cough 0.94 (0.46–1.92) 0.870
 Night sweats 0.55 (0.26–1.16) 0.116
 Loss of weight 2.33 (1.07–5.04) 0.032
 Duration of symptoms > 3 months 3.85 (0.47–31) 0.207
 No ART use during TB treatment 2.49 (1.31–4.73) 0.005 5.6 (2.9–11) < 0.001
 ART naïve 1.2 (0.66–2.2) 0.569
 OI other than TB 7.76 (3.96–15.25) < 0.001 8.5 (4–18.4) < 0.001
 CD4 counts cells/μl at TB < 200 2.02 (1.01–4.04) 0.046
 Hemoglobin < 10 g/dl 2.4 (1.3–4.5) 0.007 2.44 (1.3–4.6) 0.029
 Major Side effect 4.84 (2–12.3) 0.001 5 (1.6–17) 0.007
 IRIS 1.1 (0.53–2.27) 0.808
 Diabetes mellitus 0.049 (0–2559) 0.586
  1. TB tuberculosis, ART antiretroviral therapy, IRIS immune reconstitution inflammatory syndrome, HR hazard ratio, CI Confidence Interval. Major side effect found were Hepatoxicity (8/9), and Stevens Johnson syndrome 1/9 OI: opportunistic infection, and ART use during TB treatment: time-updated variables